STML - Stemline Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
11.83
0.00 (0.00%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close11.83
Open12.00
Bid11.87 x 3100
Ask11.90 x 4000
Day's Range11.83 - 12.10
52 Week Range3.21 - 18.22
Volume17,354,381
Avg. Volume2,358,648
Market Cap621.203M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Why Stemline Therapeutics (STML) Might Surprise This Earnings Season
    Zacks

    Why Stemline Therapeutics (STML) Might Surprise This Earnings Season

    Stemline Therapeutics (STML) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

  • 3 Small-Cap Biotech Stocks That Surged Last Week
    Motley Fool

    3 Small-Cap Biotech Stocks That Surged Last Week

    Last week, shares of these three biotech stocks rocketed higher, but their market values are still relatively small. Here's what you need to know about the businesses behind these recent stock market run-ups before thinking about adding them to a portfolio you'd like to manage successfully.

  • Here's Why Stemline Therapeutics Doubled Overnight
    Motley Fool

    Here's Why Stemline Therapeutics Doubled Overnight

    What happened Shares of Stemline Therapeutics (NASDAQ: STML) are up 153% to $12.02 at 1:11 p.m. EDT after the company announced it is being acquired by a privately held Italian pharmaceutical company, Menarini.

  • TheStreet.com

    Stemline Stock Doubles After Up to $677M Purchase Accord With Menarini of Italy

    Stemline stock more than doubled after the company agreed to be acquired for as much as $677 million by an Italian pharma and diagnostics company.

  • What You Must Know About Stemline Therapeutics, Inc.'s (NASDAQ:STML) Beta Value
    Simply Wall St.

    What You Must Know About Stemline Therapeutics, Inc.'s (NASDAQ:STML) Beta Value

    If you're interested in Stemline Therapeutics, Inc. (NASDAQ:STML), then you might want to consider its beta (a measure...

  • Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know
    Zacks

    Will Stemline Therapeutics (STML) Report Negative Q1 Earnings? What You Should Know

    Stemline Therapeutics (STML) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Wall Street Recommends Buying These 2 Falling Knives
    GuruFocus.com

    Wall Street Recommends Buying These 2 Falling Knives

    Their low debt-equity ratio reduces the investment risk Continue reading...

  • Thomson Reuters StreetEvents

    Edited Transcript of STML earnings conference call or presentation 16-Mar-20 12:00pm GMT

    Q4 2019 Stemline Therapeutics Inc Earnings Call

  • Stemline Therapeutics, Inc. Just Reported, And Analysts Assigned A US$19.75 Price Target
    Simply Wall St.

    Stemline Therapeutics, Inc. Just Reported, And Analysts Assigned A US$19.75 Price Target

    It's been a mediocre week for Stemline Therapeutics, Inc. (NASDAQ:STML) shareholders, with the stock dropping 19% to...

  • We're Hopeful That Stemline Therapeutics (NASDAQ:STML) Will Use Its Cash Wisely
    Simply Wall St.

    We're Hopeful That Stemline Therapeutics (NASDAQ:STML) Will Use Its Cash Wisely

    Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

  • Benzinga

    The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 13.) Arvinas Inc (NASDAQ: ARVN ) Baxter International ...

  • Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks
    TipRanks

    Street Watch: Top Analysts Make Moves on 3 Buy-Rated Stocks

    Onward and upward the market goes, with December providing further cheer as new record highs for the S&P 500 were notched in the last week. Giddy from 2019’s riches and ready to bring in the New Year, the optimism on the Street, following a brief slump, has been renewed.While analysts are divided as to whether the next year can follow this one’s record breaking run, one thing looks certain; investors will still be on the lookout for the right addition to their portfolio.TipRanks - a company that tracks and measures the performance of analysts - has an instrument that comes in handy here. The Daily Stock Ratings tool allows a user to see what stocks are hot and, yes, what stocks are not. Analysts’ ratings and their performances are displayed, too, further helping the intrepid investor make the right decision.Let’s have a look, then, at 3 Buy-rated stocks a number of the Street’s leading analysts recently pulled the trigger on.Stemline Therapeutics Inc (STML)With a focus on developing and bringing to market novel oncology therapies, Stemline Therapeutics has recently been turning heads on the Street.The New York based biotech has several therapies in the pipeline, but already has one on the market. Elzonris is used to treat a rare blood cancer called blastic plasmacytoid dendritic cell neoplasm (BPDCN), and was approved by the FDA in December 2018 for the treatment of adults and pediatric patients over 2 years old. The drug is currently in clinical trials to assess further indications.Cantor Fitzgerald’s Alethia Young calls Elzonris a "pipeline in a product" and believes the biotech is undervalued. Stemline’s market cap is currently $555.4 million, and Young expects sales from Elzonris for BPDCN (sans maintenance therapy) to be in the region of $150 million by 2025. We’re talking about just the US here. Furthermore, the 5-star analyst thinks the possible expansion of Elzonris into the BPDCN maintenance setting in 2021 could, by 2029, result in US sales of $223M. Young maintains that as "as investors take notice of progress in the label expansion opportunities”, the next 12 months should see Stemline’s share price take off.Accordingly, Young initiated coverage on Stemline with an Overweight rating and set a price target of $18. This implies upside potential of 62% over the next 12 months. (To watch Young’s track record, click here)The Cantor analyst’s bullish thesis is mirrored by that of the Street’s. All 5 analysts tracked over the last three months rate the stock a Buy, and therefore, Stemline has a Strong Buy consensus rating. An average price target of $22.75 outstrips Young’s target and indicates gains of 105% could be in the cards. (See Stemline stock analysis on TipRanks) X4 Pharmaceuticals Inc (XFOR)The biotech sector’s recent upturn in the market hasn’t, unfortunately, had any effect on X4 Pharmaceuticals. The rare disease focused biotech has had a rough year in the market, and its share price is down by 21% year-to-date. The word on the Street, though, is that this is all about to change.The company has several drugs in the pipeline, but its lead candidate is mavorixafor (X4P-001), currently in Phase 3 development for the treatment of WHIM syndrome. The rare, inherited condition is an immunodeficiency disease caused by genetic mutations in the CXCR4 receptor gene. Designated orphan status by the FDA in 2018, the drug is also in development for several other conditions, including Waldenström’s macroglobulinemia (WM).Roth Capital’s Zegbeh Jallah highlights XFOR’s “well experienced team” which includes Dr. Renato Skerlj, who developed the first CXCR4 antagonist (plerixafor), as making it a stand-out. Jallah also bases his bullish thesis on a “strong conviction around the clinical and commercial outlook” of mavorixafor, and “a robust pipeline of optimized CXCR4 modulators that could offer improved benefits across a broader range of diseases.” As a result, the analyst initiated coverage of X4 with a Buy rating and a price target of $20, indicating handsome upside potential of 82%. (To watch Jallah’s track record, click here)A fellow analyst praising XFOR is Oppenheimer’s Leland Gershell. The 5-star analyst expects the drug to gain approval for WHIM syndrome and remains "cautiously optimistic" about its part to play in Waldenstrom's macroglobulinemia. Leland initiated coverage with an Outperform rating and a price target of $20, too. (To watch Gershell’s track record, click here)3 other analysts have chipped in with a take on X4 over the last three months and all have reached the same conclusion: Buy. Therefore, the rare disease specialist has a Strong Buy consensus rating. The average price target of $20.25 could provide investors with gains of 84% over the next 12 months. (See X4 Pharmaceuticals stock analysis on TipRanks) See also: 3 “Strong Buy” Energy Stocks with Electric Upside PotentialiMedia Brands Inc (IMBI)Moving on from the biotech industry, we encounter a fellow struggler. Although in a completely different industry, multiplatform commerce company iMedia Brands hasn’t had much joy in 2019, either. Languishing in the doldrums, the company has a year-to-date loss of 7%.That being said, iMedia has an expanding portfolio of shopping television networks and new media businesses including ShopHQ and iMedia Web Services. November saw new additions to the list, too. The first, Float Left Interactive, an OTT (over the top) and TVE (TV everywhere) service provider, has launched a string of OTT apps and counts NBC, Comcast and CBS among its clients. The second, J.W. Hulme, is a maker of leather bags and accessories, and will get its own programming on ShopHQ's cable channel.So, with the new developments in place, is now the right time to get in on iMedia? It is according to D.A. Davidson’s Tom Forte. The 5-star analyst forecasts iMedia revenue to grow by 3% per year over the next three years and projects that by 2022, the company’s EBITDA margin will expand by almost 500 basis points to 3.1%.Furthermore, with LaVenta, the company’s new omni-channel, Spanish language, television shopping network launching in Q1 2020, Forte acknowledges iMedia’s potential for expansion outside the US.To this end, Forte initiated coverage on the interactive media company with a Buy rating, alongside a price target of $10. The bullish target indicates upside potential of a whopping 170%. (To watch Forte’s track record, click here)iMedia currently has only 1 other analyst assessing the company’s 12-month potential, but he happens to be a vocal fan, too. Lake Street’s Mark Argento reckons the next year could see iMedia’s share price reach $15, which lends itself to a massive 305% increase from the current price. (To watch Argento’s track record, click here)Put together, the media company has a Moderate Buy consensus rating and an average price target of $12.50. Potentially, then, investors could be lining their pockets with a 237% gain next year. (See iMedia price targets and analyst ratings on TipRanks)

  • Stemline Therapeutics Inc (STML): Hedge Funds Are Snapping Up
    Insider Monkey

    Stemline Therapeutics Inc (STML): Hedge Funds Are Snapping Up

    Is Stemline Therapeutics Inc (NASDAQ:STML) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]

  • Thomson Reuters StreetEvents

    Edited Transcript of STML earnings conference call or presentation 8-Nov-19 1:00pm GMT

    Q3 2019 Stemline Therapeutics Inc Earnings Call

  • TheStreet.com

    Differing Post-Earnings Tales of 2 Small-Cap Underachievers

    Shares of Stemline Therapeutics and Entercom Communications headed opposite directions last Friday after reporting results.

  • Benzinga

    The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

    The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Nov. 7.) Collegium Pharmaceutical Inc (NASDAQ: COLL ...

  • 2 Small-Cap Stocks That Could Be Righting the Ship
    TheStreet.com

    2 Small-Cap Stocks That Could Be Righting the Ship

    Stemline Therapeutics and Entercom Communications seem to have stabilized after notable declines late in the summer.

  • Stemline Therapeutics Inc (STML) Is Burning These Hedge Funds
    Insider Monkey

    Stemline Therapeutics Inc (STML) Is Burning These Hedge Funds

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • Did Changing Sentiment Drive Stemline Therapeutics's (NASDAQ:STML) Share Price Down By 41%?
    Simply Wall St.

    Did Changing Sentiment Drive Stemline Therapeutics's (NASDAQ:STML) Share Price Down By 41%?

    The simplest way to benefit from a rising market is to buy an index fund. While individual stocks can be big winners...

  • Does The Stemline Therapeutics, Inc. (NASDAQ:STML) Share Price Tend To Follow The Market?
    Simply Wall St.

    Does The Stemline Therapeutics, Inc. (NASDAQ:STML) Share Price Tend To Follow The Market?

    If you're interested in Stemline Therapeutics, Inc. (NASDAQ:STML), then you might want to consider its beta (a measure...

  • Mangrove Partners’ Return, AUM, and Holdings
    Insider Monkey

    Mangrove Partners’ Return, AUM, and Holdings

    Back in 2010, Nathaniel August, an activist investor, decided it was time to launch his own hedge fund, and he named it Mangrove Partners after a tree species that has the ability to survive extreme weather conditions such as storms and hurricanes. The idea behind this name was to symbolically present hedge fund that is […]

  • Thomson Reuters StreetEvents

    Edited Transcript of STML earnings conference call or presentation 2-Aug-19 12:00pm GMT

    Q2 2019 Stemline Therapeutics Inc Earnings Call

  • GuruFocus.com

    Stemline Therapeutics Inc (STML) CEO Ivan Bergstein Sold $515,697 of Shares

    CEO of Stemline Therapeutics Inc (30-Year Financial, Insider Trades) Ivan Bergstein (insider trades) sold 35,010 shares of STML on 08/14/2019 at an average price of $14.73 a share. Continue reading...

  • Should Stemline Therapeutics, Inc. (NASDAQ:STML) Be Your Next Stock Pick?
    Simply Wall St.

    Should Stemline Therapeutics, Inc. (NASDAQ:STML) Be Your Next Stock Pick?

    Stemline Therapeutics, Inc. (NASDAQ:STML) is a company with exceptional fundamental characteristics. Upon building up...

  • Checking In on 2 Small Biotech Names That Had Big Quarters
    TheStreet.com

    Checking In on 2 Small Biotech Names That Had Big Quarters

    Stemline Therapeutics and Flexion Therapeutics both saw their shares climb on positive news developments.